Russell Frank Company’s Acorda Therapeutics ACOR Stock Holding History

Russell Frank Company’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$6.2M	Buy	1,953 +1,450	+288%	+$6.02M	0.01%	1212
2015 Q4	$2.6M	Sell	503 -76	-13%	-$332K	﹤0.01%	1681
2015 Q3	$1.84M	Buy	579 +18	+3%	+$69.8K	﹤0.01%	1897
2015 Q2	$2.24M	Buy	561 +135	+32%	+$521K	﹤0.01%	1903
2015 Q1	$1.7M	Sell	426 -59	-12%	-$270K	﹤0.01%	1873
2014 Q4	$2.37M	Sell	485 -1,510	-76%	-$6.48M	﹤0.01%	1686
2014 Q3	$8.11M	Buy	1,995 +661	+50%	+$2.48M	0.01%	1003
2014 Q2	$4.82M	Buy	1,334 +1,030	+339%	+$4.2M	0.01%	1340
2014 Q1	$1.27M	Buy	+304	New	+$1.23M	﹤0.01%	1981
2013 Q4	–	Sell	-180	Closed	-$742K	–	3135
2013 Q3	$742K	Sell	180 -19	-10%	-$81.8K	﹤0.01%	2322
2013 Q2	$789K	Buy	+199	New	+$819K	﹤0.01%	2163

Other funds holding ACOR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Russell Frank Company's ACOR Position: Q1 2016 in Review

Russell Frank Company increased its Acorda Therapeutics (ACOR) stake by 288% in Q1 2016, buying an estimated $6.02M and bringing the position to 1,953 shares worth $6.2M. The position accounts for 0.01% of the portfolio, ranked #1212.

Russell Frank Company first reported a position in ACOR in Q2 2013 and has held it in 11 quarters since. The position peaked at $8.11M in Q3 2014. 194 funds tracked by Wall St. Rank hold ACOR as of Q1 2016.

Russell Frank Company held 1,953 shares of Acorda Therapeutics worth $6.2M as of Q1 2016.
Russell Frank Company bought 1,450 Acorda Therapeutics shares in Q1 2016, an estimated $6.02M.
Acorda Therapeutics made up 0.01% of Russell Frank Company's portfolio in Q1 2016, its #1212 holding.
Russell Frank Company first reported a position in Acorda Therapeutics in Q2 2013 and has held it in 11 quarters since.
Russell Frank Company's Acorda Therapeutics position peaked at $8.11M in Q3 2014.
194 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.